75 related articles for article (PubMed ID: 20595155)
1. Particle size matters: diagnostics and treatment of small airways involvement in asthma.
Cohen J; Postma DS; Douma WR; Vonk JM; De Boer AH; ten Hacken NH
Eur Respir J; 2011 Mar; 37(3):532-40. PubMed ID: 20595155
[TBL] [Abstract][Full Text] [Related]
2. Ciclesonide improves measures of small airway involvement in asthma.
Cohen J; Douma WR; ten Hacken NH; Vonk JM; Oudkerk M; Postma DS
Eur Respir J; 2008 Jun; 31(6):1213-20. PubMed ID: 18287130
[TBL] [Abstract][Full Text] [Related]
3. Airway responsiveness to adenosine after a single dose of fluticasone propionate discriminates asthma from COPD.
Spicuzza L; Scuderi V; Morjaria JB; Prosperini G; Arcidiacono G; Caruso M; Folisi C; Di Maria GU; Polosa R
Pulm Pharmacol Ther; 2014 Feb; 27(1):70-5. PubMed ID: 23688422
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma.
Hoshino M
Allergol Int; 2010 Mar; 59(1):59-66. PubMed ID: 20035146
[TBL] [Abstract][Full Text] [Related]
5. Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
Fardon TC; Lee DK; Hodge MR; Lipworth BJ
Ann Allergy Asthma Immunol; 2005 Sep; 95(3):259-65. PubMed ID: 16200817
[TBL] [Abstract][Full Text] [Related]
6. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction.
Luijk B; Kempsford RD; Wright AM; Zanen P; Lammers JW
Eur Respir J; 2004 Apr; 23(4):559-64. PubMed ID: 15083754
[TBL] [Abstract][Full Text] [Related]
7. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma.
van den Berge M; Luijk B; Bareille P; Dallow N; Postma DS; Lammers JW
Allergy; 2010 Dec; 65(12):1531-5. PubMed ID: 20560909
[TBL] [Abstract][Full Text] [Related]
8. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma.
Kanniess F; Richter K; Böhme S; Jörres RA; Magnussen H
Pulm Pharmacol Ther; 2001; 14(2):141-7. PubMed ID: 11273796
[TBL] [Abstract][Full Text] [Related]
9. Comparison of high-dose salmeterol/fluticasone and moderate-dose salmeterol/fluticasone plus low-dose mometasone in patients with severe persistent asthma.
Kurashima K; Kagiyama N; Takayanagi N; Sugita Y
Respirology; 2011 Jul; 16(5):784-9. PubMed ID: 21382132
[TBL] [Abstract][Full Text] [Related]
10. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma.
Fritscher LG; Rodrigues MT; Zamel N; Chapman KR
Respir Med; 2009 Feb; 103(2):296-300. PubMed ID: 18805684
[TBL] [Abstract][Full Text] [Related]
11. Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma.
Boulet LP; Turcotte H; Prince P; Lemière C; Olivenstein R; Laprise C; Larivée P; Bégin P; Laviolette M
Respir Med; 2009 Oct; 103(10):1554-63. PubMed ID: 19692221
[TBL] [Abstract][Full Text] [Related]
12. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme.
den Otter JJ; van Schayck CP; Folgering HT; van den Boom G; Akkermans RP; van Weel C
Eur J Gen Pract; 2007; 13(2):89-91. PubMed ID: 17534745
[TBL] [Abstract][Full Text] [Related]
13. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution.
de Vries TW; Rottier BL; Gjaltema D; Hagedoorn P; Frijlink HW; de Boer AH
Respir Med; 2009 Aug; 103(8):1167-73. PubMed ID: 19269801
[TBL] [Abstract][Full Text] [Related]
15. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.
Szefler SJ; Phillips BR; Martinez FD; Chinchilli VM; Lemanske RF; Strunk RC; Zeiger RS; Larsen G; Spahn JD; Bacharier LB; Bloomberg GR; Guilbert TW; Heldt G; Morgan WJ; Moss MH; Sorkness CA; Taussig LM
J Allergy Clin Immunol; 2005 Feb; 115(2):233-42. PubMed ID: 15696076
[TBL] [Abstract][Full Text] [Related]
16. Are we overlooking persistent small airways dysfunction in community-managed asthma?
Anderson WJ; Zajda E; Lipworth BJ
Ann Allergy Asthma Immunol; 2012 Sep; 109(3):185-189.e2. PubMed ID: 22920073
[TBL] [Abstract][Full Text] [Related]
17. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
Medley H; Orozco S; Allen A
Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
[TBL] [Abstract][Full Text] [Related]
19. Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma.
Cox CA; Boudewijn IM; Vroegop SJ; Schokker S; Lexmond AJ; Frijlink HW; Hagedoorn P; Vonk JM; Farenhorst MP; Ten Hacken NHT; Kerstjens HAM; Postma DS; van den Berge M
Respir Med; 2017 Sep; 130():35-42. PubMed ID: 29206631
[TBL] [Abstract][Full Text] [Related]
20. Methacholine vs adenosine on intra and extrathoracic airway hyperresponsiveness in patients with cough variant asthma.
Ribeiro M; Pereira CA; Nery LE; Beppu OS; Silva CO
Allergy; 2008 May; 63(5):527-32. PubMed ID: 18394126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
